Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Zentalis Pharmaceuticals, Inc. (ZNTL)

Zentalis Q3 2026 net loss widens to $28.8 million; cash $228.9 million, runway into 1H 2028

Mixed Impact 3 of 5 earnings

Zentalis reported a third-quarter 2026 net loss of $28.8 million, up from $26.7 million a year earlier, while the loss per share improved to $0.34 from $0.37 as the share count rose after an August 2026 offering. Operating expenses fell to $31.2 million from $33.7 million, and the company said its cash runway extends into the first half of 2028. It also said it plans to discuss DENALI data with the FDA in 2027 and expects a DENALI topline readout in the first half of 2027.

Key points

  • Net loss of $28.8 million for the quarter, compared with $26.7 million for the third quarter of 2025
  • Net loss per share of $0.34, compared with $0.37; weighted shares rose to 84.6 million from 72.1 million
  • Total operating expenses of $31.2 million, compared with $33.7 million; investment and other income fell to $2.5 million from $7.0 million
  • Cash, cash equivalents and marketable securities of $228.9 million at September 30, 2026, up from $174.6 million at June 30, 2026, including August 2026 offering proceeds

The filing

CompanyZentalis Pharmaceuticals, Inc. (ZNTL)
Form8-K, current report
Filed with the SECNov 9, 2026, 4:08 PM ET
Accession number0001725160-26-000069

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 6:16 PM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.